Related Experiment Video
Updated: Aug 22, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Meeting an un-MET need: Targeting MET in non-small cell lung cancer
Elena Michaels1, Christine M Bestvina2
1Department of Medicine, University of Chicago, Chicago, IL, United States.
Abstract:
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). MET exon 14 skipping mutations occur in 3-4% of patients with NSCLC, while MET amplifications are found in 1-6% of patients. The most effective method for detection of MET amplification is fluorescent in situ hybridization (FISH) and of MET exon 14 skipping mutations is RNA-based next generation sequencing (NGS). Immunohistochemistry (IHC) is an alternative method of diagnosis but is not as reliable. Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit. However, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy. Both drugs have an acceptable safety profile with the most common treatment-related adverse event being peripheral edema. One of the most frequent resistance mechanisms to EGFR inhibition with osimertinib is MET amplification. There is interest in combining EGFR inhibition plus MET inhibition in an attempt to target this resistance mechanism. Additional ways of targeting MET alterations are currently under investigation, including the bi-specific antibody amivantamab. Additional research is needed to further understand resistance mechanisms to MET inhibition. There is limited research into the efficacy of immune checkpoint inhibition for MET-altered NSCLC, though some data suggests decreased efficacy compared with wild-type patients and increased toxicity associated with the combination of immunotherapy and MET TKIs. Future directions for research will include combination clinical trials and understanding rational combinations for MET alterations.
Insights
MET pathway alterations, including MET exon 14 skipping mutations and amplifications, impact non-small cell lung cancer (NSCLC) prognosis. Newer MET tyrosine kinase inhibitors (TKIs) show improved efficacy, but resistance mechanisms and immunotherapy combinations require further research.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MET pathway is frequently altered in non-small cell lung cancer (NSCLC), driven by MET exon 14 skipping mutations, gene amplification, or overexpression.
- These MET alterations are associated with a poor prognosis in NSCLC patients.
- MET exon 14 skipping mutations affect 3-4% of NSCLC patients, and MET amplifications are found in 1-6%.
Purpose of the Study:
- To review the diagnostic methods, therapeutic strategies, and emerging research directions for MET-altered NSCLC.
- To highlight the clinical efficacy and safety of novel MET tyrosine kinase inhibitors (TKIs).
- To discuss resistance mechanisms and potential combination therapies for MET-targeted treatment.
Main Methods:
- Review of current literature on MET pathway alterations in NSCLC.
- Analysis of diagnostic techniques including FISH, RNA-based NGS, and IHC.
- Evaluation of clinical data for MET TKIs (capmatinib, tepotinib) and other targeted agents (amivantamab).
Main Results:
- Fluorescent in situ hybridization (FISH) and RNA-based next-generation sequencing (NGS) are the most effective methods for detecting MET amplification and exon 14 skipping mutations, respectively.
- Selective MET TKIs like capmatinib and tepotinib demonstrate improved efficacy and an acceptable safety profile, with peripheral edema as a common adverse event.
- MET amplification is a known resistance mechanism to EGFR inhibitors like osimertinib, prompting interest in combination therapies.
Conclusions:
- Novel MET TKIs represent a significant advancement in treating MET-altered NSCLC.
- Understanding and overcoming resistance mechanisms, particularly in combination therapies with EGFR inhibitors or immunotherapy, is crucial for future treatment strategies.
- Further research into combination clinical trials and rational combinations is essential for optimizing outcomes in MET-altered NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
